QTc prolongation is a common black box warning within medication labeling. However, it is unclear if QTc prolonging drugs carry the same risk for torsade de pointes as primary or congenital prolongation. The majority of previous studies regarding antipsychotics are limited by a variety of factors. This was a retrospective, cohort study amongst 114 patients at the FHCC to examine the risk of developing QTc prolongation and torsade de pointes in relation to antipsychotic dosing. The primary objective is to determine the incidence rate and mean of QTc prolongation stratified to dose of five antipsychotics. The secondary objective is to determine the incidence of QTc of ≥ 500 msecs and torsades de pointes stratified to dose. The frequency of QTc prolongation was analyzed using chi-square and Fischer's exact test as appropriate with a p < 0.05 being labeled as significant. The average length of QTc prolongation stratified to the dose of antipsychotic was analyzed using linear regression analysis. Dose dependency of QTc prolongation with the five antipsychotic drugs of interest (haloperidol, ziprasidone, olanzapine, risperidone, and ziprasidone) was not supported in this study based on the non-significant linear regression analyses.
Introduction


QTc prolongation is a common black box warning for many medications and a common reason for non-approval or withdrawal from market (Girardin et al., 2013; Glassman & Brigger, 2001 ). Drug-induced prolonged QTc was first discovered in cardiac drugs and limited to this class until 1992, when the Federal Drug Administration (FDA) added a black box warning of QTc prolongation to the first-generation antihistamine, terfenadine (Glassman & Brigger, 2001) . Primary or congenital prolongation of the corrected QT interval (QTc) had been known for some time and was associated with a higher risk for cardiac arrhythmias, primarily ventricular, and sudden death (Camm et al., 2012; Glassman & Brigger, 2001) .
The QT interval measures the time between the onset of electrical depolarization of the ventricles (Q wave) and the end of repolarization (T wave). This is measured via an electrocardiographic (ECG) machine and corrected for heart rate (QTc) as it shortens with increasing heart rates (Glassman & Brigger, 2001 a QTc ≥ 500 milliseconds (ms) or an increase ≥ 60 ms from baseline, in secondary, drug-induced, is considered clinically relevant for increasing the risk of ventricular arrhythmias, including torsade de points (Camm et al., 2012) In 1966 this term was developed to describe a malignant polymorphic ventricular arrhythmia characterized by a twisting pattern of the QRS complex and associated with syncope and sudden death (Glassman & Brigger 2001) . Most episodes are transient and self-limited, but 1-20% can lead to sudden death (Berling & Isbister, 2015; Camm et al., 2012; Girardin et al., 2013; Polcwiartek et al., 2015) . Since this term was coined in congenital long QT syndrome, it is still unclear if drugs that prolong the QTc interval behave similarly and carry the same risk for inducing torsade de pointes (Glassman & Brigger, 2001) . It became clear that antipsychotics could influence the QT interval in 1996 when a new atypical antipsychotic, sertindole, was not approved in the United States due to QTc prolongation and 12 sudden cardiac deaths in the trials (Glassman & Brigger, 2001 ). There had been reports of sudden cardiac deaths associated with antipsychotics, particularly thioridazine, for years before sertindole, but this was the first FDA intervention in the matter. In vitro studies have shown the ability of antipsychotics to block the potassium rectifier channel (I Kr ) that is involved in the repolarization of the ventricles (Berling & Isbister, 2015; Fujii et al., 2014 , Polcwiartek et al., 2015 , Vieweg et al., 2013 . However, in vitro studies have shown that despite risperidone's ability to inhibit this channel by 80% at the highest concentrations, it had minimal effect on cardiac conduction (Berling & Isbister, 2015; Vieweg et al., 2013) . Additionally, a study by Pfizer failed to display any additive QTc prolonging effects of potent CYP inhibitors in the presence of six antipsychotics, which included haloperidol, olanzapine, quetiapine, risperidone, thioridazine and ziprasidone. Berling and Isbister demonstrated even in the situation of antipsychotic overdose prolongation of the QTc only occurred in 3-56% of patients depending on the antipsychotic and only one patient out of 494 developed TdP after an overdose of thioridazine (2015) . Studies that did report TdP occurring in patients on antipsychotics found most, if not all, had at least one other risk factor present (Vieweg et al., 2014; Polcwiartek et al., 2015) . Sudden cardiac death from TdP is also so rare in this population a five-year cross-sectional study calculated 3000 patients would need to be screened by ECG in order to prevent one death (Poncet et al., 2015) . Thus the mechanism of action these antipsychotics have on cardiac condition is not a straightforward interaction, but rather quite complex and not completely understood.
Additionally, many studies used antipsychotics at higher doses than used in common practice or even used multiple antipsychotics with cumulative doses higher than those on monotherapy (Berling & Isbister, 2015; Fujii et al., 2014; Glassman & Brigger, 2001 ). In the majority of studies with haloperidol, for example, the agent was administered intravenously and in an acute care or intensive care patients with intubation-related agitation. Dosing protocols vary, but one hospital study reported starting with 35-55 mg and doubled the dose every 20 minutes until the agitation was controlled and then that dose was given every 6 hours. These exceptionally large doses, up to 400mg in 24 hours, did lead to eight cases of torsade de pointes, with 41 controls in an observational case-control study design (Sharma, Rosman, Padhi, & Tisdale, 1998) . The study by Pfizer mentioned previously compared the highest doses of the dosing range of antipsychotics in comparison to their relatively new atypical, ziprasidone (Geodon), and showed an average of < 10 ms versus < 20 ms QTc prolongation, respectively (Harrigan et al., 2004) . Thus for approval, the FDA required a large post-marketing study to further evaluate the cardiac outcomes with ziprasidone. This large sample trial using real world dosing failed to demonstrate an increased risk of non-suicide mortality in patients taking ziprasidone in comparison to olanzapine, an atypical that has been shown to have the lower QTc effects. Due to the study design neither the dosing of the antipsychotics, incidence of QTc prolongation or torsade de pointes was evaluated. Additionally, ANTIPSYCHOTIC DOSING ON QTC PROLONGATION 289 some studies also used normal health persons as a comparison to those with schizophrenia on antipsychotics (Reilly, Ayis, Ferrier, Jones, & Thomas, 2000) . One study demonstrated that the QTc of non-medicated schizophrenics was longer than those of normal healthy subjects. This is potentially related to the variant of potassium channel gene that is responsible for congenital QTc prolongation as some studies have shown that variants in this gene also lead to a risk of developing schizophrenia (Fujii et al., 2014) . Also, patients with schizophrenia are at more risk for cardiac disease and sudden death, especially since many are heavy smokers (Glassman & Brigger, 2001) . Thus the large majority of previous studies are limited by the fact that they used comparisons to non-schizophrenics as well as abnormally large doses or no stratification to dosing. To the best of the authors' abilities, no studies at present could be found evaluating real-world doses of antipsychotics, incidence of QTc prolongation and torsade de points and the mean of prolongation stratified to dose. Fujii et al. (2014) stated that they found an association between dosing, polypharmacy and QTc prolongation; however no doses were actually published. Another study found mixed results when plotting various antipsychotic doses against QTc, however all of the cases involved overdoses (Berling & Isbister, 2015) .
This study was aimed at evaluating the potential dose-dependence of QTc prolongation in antipsychotics amongst the veteran population in order to help clarify when prescribers should be monitoring ECGs in these patients. The primary objective was to determine the incidence rate and mean of QTc prolongation stratified to dose of five antipsychotics (haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone). The secondary objective was to determine the incidence of QTc of ≥ 500 msecs and torsades de pointes stratified to dose.
Materials and Methods
This study is a retrospective, cohort study comparing the frequency of normal and prolonged QTc intervals in participants taking one of the antipsychotic drugs of interest as well as the mean QTc length stratified to the dose of antipsychotic. This study was approved by the Captain James A. Lovell FHCC Institutional Review Board. Veterans aged 18 years of age or older seen at the FHCC for care from 01 July 2004 to 01 July 2014 were included in the study if they met the following criteria: prescribed haloperidol, olanzapine, quetiapine, risperidone, and/or ziprasidone on a scheduled basis (no prn dosing) for ≥ 7 days; baseline (≤ 12 months prior to first dose) and during treatment ECGs (≥ 7 days after first dose) were included in the study. Participants were excluded if they had congenital QTc prolongation or were non-veterans (such as active duty participants).
Potentially eligible patients were identified via a Computerized Patient Records Systems (CPRS) search for haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone outpatient prescriptions during the time period specified. With this information, the following additional data were gathered through CPRS: demographic information (age, gender, race); antipsychotic medication and dose; electrocardiographic (ECG) imaging and reports; concurrent medications and past use of known QTc prolonging drugs; laboratory values (blood glucose, A1C levels, electrolyte levels, liver function tests (LFTs), serum creatinine and kidney function, substance use urinalyses, thyroid function tests (TSH, T 4 )); and vital signs (heart rate, blood pressure, and body measure index (BMI)). The average length of QTc prolongation from baseline was recorded along with the frequency of QTc ≥ 500 ms and frequency of specified lengths the QTc interval was prolonged from baseline (≥ 10, ≥ 20, ≥ 30, ≥ 40, ≥ 50, ≥ 60).
All demographic and characteristic variables were analyzed using chi-square/Fischer's exact test or student's t-test as appropriate. Student's t-tests were run to analyze the average length of QTc prolongation ANTIPSYCHOTIC DOSING ON QTC PROLONGATION 290 from baseline. Additionally, the average length of the QTc prolongation stratified to the dose of antipsychotic was analyzed using linear regression. All statistical tests were run with a significance criterion of 0.05.
Results
A total of 500 patient charts were reviewed and 114 met inclusion criteria (386 were excluded). A total of 12 participants on haloperidol, 29 on olanzapine, 32 on quetiapine, 20 on risperidone, and 21 on ziprasidone were included. Those participants who experienced QTc prolongation are referred to as the "change group" and those who did not experience QTc prolongation are referred to as the "no change group". All statistically significant differences as defined by a p < 0.05 are bolded in the following tables. 
Haloperidol
Of the 12 total participants in the haloperidol group, only 2 experienced QTc prolongation and were included in the change group. The other 10 participants in the haloperidol did not experience QTc prolongation and were thus included in the no change group.
In regards to the background data at the time of the baseline ECG, the group with no change had a significantly higher BMI and significantly more concomitant medications that also have the potential to increase the QT interval (Table 2 ). For the background data at the time of the ECG taken while taking haloperidol, there was a significant difference in the no change group that included a longer time period between the first dose to the time of the first ECG, averaging 3.2 months, and again significantly more concomitant medications that also have the potential to increase the QT interval. One patient experienced a QT > 500 msec but no torsade de pointes (Table 4) . Interestingly, the dose in the no change group was statistically significantly higher than the dose in the change group. As seen in Table 6 , one individual in the change group experienced a QTc increase between 20-30 ms from baseline, while another had a greater than 60 msec change. No significant results were found for the linear regression analysis for change in QTc with respect to dose.
Olanzapine
Of the 29 total participants in the olanzapine group, 20 experienced QTc prolongation and were placed in the change group, leaving 9 participants who did not experience QTc prolongation and were thus placed in the no change group.
As seen in Table 2 , the no change group had a significantly higher systolic BP and interestingly a higher baseline QT interval at the baseline ECG time. However, the change group had a significantly higher QT interval in comparison to the no change group at the treatment ECG. Note that two patients did have a > 500 msec QT interval. However, as seen on Table 6 , here only one of these also fell into the category of > 60 msec change. Half of the QTc prolongation was 29 msec or less. Linear regression analysis was non-significant.
Quetiapine
Of the 32 total participants in the quetiapine group, 11 participants experienced QTc prolongation and were placed in the change group, leaving 21 participants who did not experience QTc prolongation and placed in the no change group.
As seen on Table 1 , the change group was significantly older than that of the no change group. Similar to the background data for olanzapine, quetiapine's no change group also had a significantly longer QT interval at baseline (Table 2 ). Yet again, similar to olanzapine, quetiapine also showed a significantly longer QT interval at the treatment ECG in the change group. The only other significant difference was the higher systolic and diastolic BPs in the no change group. Neither group had a QT of greater than 500 msecs. There was a statistically significant difference amongst doses that appears to correlate with the hypothesis that those with QTc prolongation or in the change group were taking a significantly higher dose of quetiapine than those in the no change group (Table 4) . Additionally, the serum concentrations in the change group could be significantly higher due to a statistically significant elevation of SCr in the change group (Table 5) . However, linear regression analysis for quetiapine was also non-significant. Note, only one participant had a greater or equal to 60 msec change from baseline (Table 6) .
Risperidone
Of the 20 total participants in the risperidone group, 14 experienced QTc prolongation and were placed in ANTIPSYCHOTIC DOSING ON QTC PROLONGATION 294 the change group. Thus, 16 participants did not experience QTc prolongation and were placed on the no change group.
Similar to the last two medications, here again we see the no change group had a significantly longer baseline QT interval at baseline ( Table 2 ). As seen in Table 5 , there was a statistically significant elevation in TSH levels in the change group at the time of the treatment ECG (Tables 4 and 5 ). There were zero cases of a QTc 500msec or greater (Tables 2 and 4) . Additionally, no participants had a greater or equal to 50 msec change from baseline. The large majority had a 29 msec change or less (Table 6 ). Again, no significant results were found in the linear regression analysis.
Ziprasidone
Of the 21 total participants in the ziprasidone group, 14 participants experienced QTc prolongation and were placed on the change group, leaving 7 participants who did not experience a QTc prolongation and were placed in the no change group.
As seen on Table 2 , the change group had a significantly longer time period of time from baseline ECG to time of first dose of ziprasidone. As seen on Table 4 , again the change group had a significantly longer time period of time from time of first dose of ziprasidone to treatment ECG, averaging 22.7 months. They also had a significantly longer treatment QT interval, including one participant who had a QTc of greater or equal to 500 msecs.
Despite having one participant who had a QTc of greater than 500 msec, no participants had a greater than or equal to 60 msec change from baseline (Table 6 ). Again, no significant results were found in regards to the linear regression analysis.
Discussion
Dose dependency of QTc prolongation with the five antipsychotic drugs of interest (haloperidol, ziprasidone, olanzapine, risperidone and ziprasidone) was not supported in this study based on the non-significant linear regression analyses. Additionally, the group of participants who experienced no QTc prolongation were taking a statistically significant higher dose of haloperidol in comparison to the group who did experience QTc prolongation. While in comparison, those receiving quetiapine who experienced QTc prolongation were taking a statistically significantly higher dose than those without QTc prolongation (p = 0.02). However, when looking at each individual drug it is difficult to draw conclusions due to the small sample size, especially with haloperidol having only two participants who experienced QTc prolongation. Similar to several previous studies zero cases of torsade de pointes or sudden cardiac death were found in this study (Glassman & Brigger, 2001; Harrigan et al., 2004; Vieweg et al., 2013) . There were only five cases of a QTc > 500 msec and only three cases of a > 60 msec change from baseline and thus were relatively rare. However, unlike the previous study done by Harrigan et al., several larger changes in QTc prolongation from baseline were seen (2004), but none were found to be associated to the dose unlike the studies done by Fujii et al. (2014) , and Berling and Ibister (2015) . Whether the differences in baseline/treatment characteristics could be a factor is difficult to determine. Several differences in baseline/treatment characteristics were actually contradictory. Despite QTc prolongation being associated with bradycardia, those with QTc prolongation in the ziprasidone group actually had a significantly higher heart rate in comparison to those who did not experience QTc prolongation (Berling & Isbister, 2015; Glassman & Brigger, 2001) . Additionally, those in the no change ANTIPSYCHOTIC DOSING ON QTC PROLONGATION 295 haloperidol group had significantly more medications that could have also contributed to a prolonged QTc and yet they either had no change or a decrease in the QT interval at the time of the treatment ECG. As seen in olanzapine, quetiapine and risperidone there was a significantly longer QTc at baseline amongst those who experienced no change/QTc prolongation at the time of the treatment ECG. Thus potentially furthering the notion that antipsychotic medications do not have a significant interaction with the QT interval or at least that the interaction with the QT interval is quite complicated that not only does not depend on dose but also cannot necessarily be predicted by those with a prolonged QTc at baseline.
The strengths of this study include the number of charts that were reviewed over a long time span of 10 years as well as having a similar comparison group. Additionally, a large number of variables both at the time of the baseline ECG and treatment ECG were collected. However, the inability to neither control nor account for every factor influencing the QT interval is a limitation of this study. The other limitations of this study include the retrospective study design, inclusion of a limited number of antipsychotics, inability to obtain a true baseline ECG free of any QTc prolonging medications and the interval time period for treatment ECG from first dose of antipsychotic. While the treatment ECG had to be 7 days or greater after the first dose of the antipsychotic, there was no limitation as to how long it could be after that first dose. As long as the participants were still on the antipsychotic of interest, it was considered a treatment ECG. Lastly, this study is done in the veteran population living in and around North Chicago, IL thus limiting its generalizability to the general population.
It is the goal of the authors that this study may serve as a pilot study for a much larger and comprehensive study into the dose relationship with antipsychotic drugs as well as help promoting further exploration regarding dose relationship of QTc prolongation for other medication classes. Based our findings and in light of previously published data from several larger and more comprehensive studies, the risk of torsade de pointes and sudden cardiac death with antipsychotic drugs in relation to QTc prolongation is minimal if not completely absent (Berling & Isbister, 2015; Glassman & Brigger, 2001; Harrigan et al., 2004; Vieweg et al., 2013) . There is definitely a risk of a small to moderate increase in the QT interval with these medications, but it does not appear dose related and is difficult to predict based on background data including baseline QT intervals. Based on the results of this study, it is likely that frequent monitoring of the QT interval is unnecessary with these drugs. Additionally, it is not only unnecessary but also potentially harmful for the patient's mental health to be permanently discontinuing these medications when prescribing other QTc prolonging drugs like antibiotics that is commonly seen in acute and intensive care unit practice, especially if such agents will not be used for extended periods of time.
